The company identified a growing interest in therapeutic peptides within the pharmaceutical industry, evidenced by the more than 80 peptide drugs on the market
CordenPharma has introduced PeptiSystems technology at its peptide manufacturing facility in Frankfurt, DE to reduce the footprint impact and improve the process mass intensity (PMI) of its manufacturing processes.
For the company, PMI and E-Factor are currently the most favourable metrics to quantify the impact of the technology. The Green Chemistry Institute Pharmaceutical Roundtable selected PMI as its preferred mass-based Green metric.
PeptiSystems’ technology is designed to enable manufacturing of peptides in continuous mode, reducing solvent consumption and corresponding waste by at least 40% in all peptides produced by solid-phase peptide synthesis. In addition to improving the carbon footprint in peptide manufacturing, continuous in-line monitoring aims to provide greater synthesis control and a more efficient manufacturing process.
The company identified a growing interest in therapeutic peptides within the pharmaceutical industry, evidenced by the more than 80 peptide drugs on the market.
Solvents represent the majority of the waste generated in chemical processes, especially for solid-phase peptide synthesis. Using greener solvents, or finding ways to reduce or recycle solvents, is therefore very valuable. The waste cogeneration in peptide production has been reported to be in the multi-ton range for each kilogram of produced peptide vs hundreds of kilograms for small-molecule synthesis.
“With the installation of PeptiSystems’ first innovative equipment in our R&D Peptide Centre of Excellence in Germany, we are proud of this contribution towards reducing our process mass intensity. This successful milestone represents one of our global initiatives to improve our footprint and reduce manufacturing costs," said Dr Matthieu Giraud, Director, Global Peptide, Lipids & Carbohydrates Platforms, CordenPharma International.